36
2022Dice Medical Communications
AGENCY STATEMENT
Dice is an independent communications agency that works with our clients to help launch, build, and continually develop great pharmaceutical brands. We do this by creating Pharmacohesion™

- Agency description
Dice Medical Communications is an independent communications agency that partners with our clients to help launch, build, and continually develop great pharmaceutical brands. We do this by creating Pharmacohesion™.
Pharmacohesion™ helps brands thrive by continually shaping and adapting the conversation with all stakeholders, in a consistent, cohesive way.
Brands nurtured with Pharmacohesion™ thrive because:
- customers, whether they are prescribers, payors, carers or patients, know exactly what to expect from your brand in terms of how it impacts on their lives.
- your brand communication is always in tune with therapeutic sentiment which also helps to withstand competitive challenges.
We create Pharmacohesion™ by bringing together insights, strategy, execution, and measurement to your brands.
- We use our network to uncover your customers’ mindsets, generating INSIGHTS that matter
- We integrate these insights into your plans – defining and refining STRATEGY based on our in-depth understanding of the market situation
- We deliver impactful, strategically-aligned tactical initiatives across all channels: EXECUTION that captures your brand values in a context that is meaningful for all your customers
- Our continued rigorous analysis helps MEASURE success and further refine customer insights, delivering ROI.
Pharmacohesion™ helps your brands fulfil the ambitions of the scientists who developed them: to transform the lives of patients with an unmet medical need. Get in touch to discuss how we can create Pharmacohesion™ for your brands.
- Contact details
- The Yard, Ground Floor, 14-18 Bell Street, Maidenhead, SL6 1BR
- (+)44 (0) 1628 397 830
- hello@dice-comms.co.uk
- http://www.dice-comms.co.uk/
- Key contact
- Matthew Dickinson
- Managing Director
- hello@dice-comms.co.uk
- (+)44 (0) 1628 397 830
- 2022 Agency Data
-
2021 awardsTotal staff25-49 staffBillings from UK creative healthcare workHealthcare staff25-49 staffTotal agency billingsAgency ageBetween 10 and 15 yearsSocial media footprintStatusINDEPENDENTApproximate percentage of advertising, branding, creative or design work in the UK healthcare market60-69%
- This information was supplied or confirmed by Dice Medical Communications. Bar charts are indicative only, with 100% being the maximum score allocated across all agencies. Billings from UK creative healthcare work are not a subset of total annual billings, and so may show a higher rating.
- Ranking factors contributing to agency score
- This chart shows the relative factors that contributed to the agency's overall ranking.
Latest content from Dice Medical Communications on PMHub
- Early communications in Pharma: How effective pre-approval comms delivers launch success
- What communications are required for a successful launch
Dice Medical Communications - Science for science sake
- Like great works of art, there was no ‘reason’ for certain scientific endeavours, but this ‘just for the sake of it’ philosophy is now delivering tangible benefits. (article written 3rd of March 2021).
Dice Medical Communications - Measurement in Med Comms: Striving for Creative Effectiveness
- How to achieve creative success in Med Comms (Article written 6th Jan 2020)
Dice Medical Communications



COVID-19 Updates and Daily News
- Associate Director - Global Healthcare Consulting
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Technical Sales Representative
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- Strategy Director - Healthcare Advertising
- Highly competitive salary
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
Quick links
Latest intelligence
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
- Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......
- Paul Hutchings, founder of fox&cat, writes on the role of humour in healthcare comms: PharmaComms 2023...
- MHRA to introduce new UK clinical trials framework
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- Roche and Eli Lilly to collaborate on Alzheimer’s disease blood test
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- Novo Nordisk and Dewpoint partner on insulin resistance drug candidates
- MSD’s Keytruda to be made available in England for advanced cervical cancer patients
- Boehringer Ingelheim and Covant to collaborate on cancer immunotherapies
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Regeneron and Sonoma partner on autoimmune disease therapies
- Improving cardiovascular disease care and awareness
- PMGroup announces launch of new recruitment platform PharmaRole
- Team ITG appoints Gerhard Arnhofer as head of customer strategy for life sciences division
- Locus Biosciences announces first patient treated in urinary tract infection trial
- The state of pharma customer experience
- MHRA to introduce new UK clinical trials framework
- Takeda presents positive phase 2b results for TAK-279 in plaque psoriasis
- Sanofi/Regeneron’s Dupixent approved by EC for atopic dermatitis in children